[Preserving ovarian function in the treatment of epithelial and special (other) malignant ovarian tumors].
About 90% of malignant tumors of the ovary in Scandinavia develop from the germinal epithelium. There are great differences in the incidence rates between countries in the Western world and in Africa and Asia. The WHO classification of ovarian malignancies is generally used. The epithelial tumors comprise the serous, mucinous, endometrioid, clear cell, undifferentiated and mixed true carcinomas. In addition, borderline lesions of especially the serous and mucinous types are of interest when the question of preservation of ovarian function comes into notice. Conservative surgery, which means removal of only the afflicted ovary should be restricted to young women of the childbearing age who want to preserve the possibility of becoming pregnant. However, certain prerequisites must be fulfilled. The tumor must be located to one ovary only (Stage Ia) and must be either a borderline lesion or a Grade 1 true carcinoma of either the serous, mucinous or endometrioid type. There must be no ascites and peritoneal washings must be negative for cancer cells. Germ cell tumors are usually found in young women. Only the dysgerminomas are regularly bilateral in 10-15% of the cases. All other germ cell tumors are rarely bilateral. But both in borderline lesions, Grade 1 true carcinomas, and in germ cell tumors, a biopsy of the normal looking contralateral ovary should always be performed. Endodermal sinus tumors and immature teratomas may well be treated conservatively by surgery, but modern triple chemotherapy (VAC, PVB) must be added. Granulosa theca cell tumors are bilateral in only about 5% of the cases.(ABSTRACT TRUNCATED AT 250 WORDS)
Kolstad
P
P
Radium Hospital Norwegen, Abteilung für gynäkologische Onkologie und Norsk Hydrós Institut für Krebsforschung Oslo.
D000328:Adult; D002277:Carcinoma / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000532:radiotherapy; D005260:Female; D006106:Granulosa Cell Tumor / Q000532:radiotherapy; D006801:Humans; D007984:Leydig Cell Tumor / Q000532:radiotherapy; D008649:Mesonephroma / Q000532:radiotherapy; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000532:radiotherapy; D009378:Neoplasms, Multiple Primary / Q000532:radiotherapy; D010050:Ovarian Function Tests; D010051:Ovarian Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D013724:Teratoma / Q000532:radiotherapy; D013798:Thecoma / Q000532:radiotherapy
Erhaltung der Ovarialfunktion in der Behandlung der epithelialen und speziellen (anderen) malignen Ovarialtumoren.